|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gianferante DM, Mirabello L and Savage SA:
Germline and somatic genetics of osteosarcoma-connecting aetiology,
biology and therapy. Nat Rev Endocrinol. 13:480–491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fagioli F, Aglietta M, Tienghi A, Ferrari
S, del Prever Brach A, Vassallo E, Palmero A, Biasin E, Bacci G,
Picci P and Madon E: High-dose chemotherapy in the treatment of
relapsed osteosarcoma: An Italian sarcoma group study. J Clin
Oncol. 20:2150–2156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wada T, Isu K, Takeda N, Usui M, Ishii S
and Yamawaki S: A preliminary report of neoadjuvant chemotherapy
NSH-7 study in osteosarcoma: Preoperative salvage chemotherapy
based on clinical tumor response and the use of granulocyte
colony-stimulating factor. Oncology. 53:221–227. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghosh T, Varshney A, Kumar P, Kaur M,
Kumar V, Shekhar R, Devi R, Priyanka P, Khan MM and Saxena S:
MicroRNA-874-mediated inhibition of the major G1/S phase
cyclin, CCNE1, is lost in osteosarcomas. J Biol Chem.
292:21264–21281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li D, Wang H, Song H, Xu H, Zhao B, Wu C,
Hu J, Wu T, Xie D, Zhao J, et al: The microRNAs miR-200b-3p and
miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and
motility of breast cancer cells. Oncotarget. 8:85276–85289.
2017.PubMed/NCBI
|
|
13
|
Huang RS, Zheng YL, Zhao J and Chun X:
microRNA-381 suppresses the growth and increases cisplatin
sensitivity in non-small cell lung cancer cells through inhibition
of nuclear factor-kB signaling. Biomed Pharmacother. 98:538–544.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao F, Pu Y, Qian L, Zang C, Tao Z and
Gao J: MiR-20a-5p promotes radio-resistance by targeting NPAS2 in
nasopharyngeal cancer cells. Oncotarget. 8:105873–105881. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Liu X and Lu YX: MicroRNA-143
regulates the proliferation and apoptosis of cervical cancer cells
by targeting HIF-1α. Eur Rev Med Pharmacol Sci. 21:5580–5586.
2017.PubMed/NCBI
|
|
16
|
He Y and Yu B: MicroRNA-93 promotes cell
proliferation by directly targeting P21 in osteosarcoma cells. Exp
Ther Med. 13:2003–2011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin W, Zhu X, Yang S, Chen X, Wang L,
Huang Z, Ding Y, Huang L and Lv C: MicroRNA-203 inhibits
proliferation and invasion, and promotes apoptosis of osteosarcoma
cells by targeting Runt-related transcription factor 2. Biomed
Pharmacother. 91:1075–1084. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Z, Xu H, Meng Y and Kuang Y: miR-944
acts as a prognostic marker and promotes the tumor progression in
endometrial cancer. Biomed Pharmacother. 88:902–910. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie H, Lee L, Scicluna P, Kavak E, Larsson
C, Sandberg R and Lui WO: Novel functions and targets of miR-944 in
human cervical cancer cells. Int J Cancer. 136:E230–E241. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He H, Tian W, Chen H and Jiang K: MiR-944
functions as a novel oncogene and regulates the chemoresistance in
breast cancer. Tumour Biol. 37:1599–1607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Zhang F, Zhang Z, Wang D, Cui B,
Zeng F, Huang L, Zhang Q and Sun Q: High expression levels of Cyr61
and VEGF are associated with poor prognosis in osteosarcoma. Pathol
Res Pract. 213:895–899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun
YQ and Zhang CQ: Prognostic significance of VEGF expression in
osteosarcoma: A meta-analysis. Tumour Biol. 35:155–160. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mei J, Gao Y, Zhang L, Cai X, Qian Z,
Huang H and Huang W: VEGF-siRNA silencing induces apoptosis,
inhibits proliferation and suppresses vasculogenic mimicry in
osteosarcoma in vitro. Exp Oncol. 30:29–34. 2008.PubMed/NCBI
|
|
25
|
Peng N, Gao S, Guo X, Wang G, Cheng C, Li
M and Liu K: Silencing of VEGF inhibits human osteosarcoma
angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT
signaling pathway. Am J Transl Res. 8:1005–1015. 2016.PubMed/NCBI
|
|
26
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen L, Li Y, Jiang Z, Zhang Y, Yang B and
Han F: miR-944 inhibits cell migration and invasion by targeting
MACC1 in colorectal cancer. Oncol Rep. 37:3415–3422. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan T, Chen W, Yuan X, Shen J, Qin C and
Wang L: miR-944 inhibits metastasis of gastric cancer by preventing
the epithelial-mesenchymal transition via MACC1/Met/AKT signaling.
FEBS Open Bio. 7:905–914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu M, Zhou K and Cao Y: MicroRNA-944
affects cell growth by targeting EPHA7 in non-small cell lung
cancer. Int J Mol Sci. 17:pii: E1493. 2016. View Article : Google Scholar
|
|
31
|
Ji YN, Wang Q, Li Y and Wang Z: Prognostic
value of vascular endothelial growth factor A expression in gastric
cancer: A meta-analysis. Tumour Biol. 35:2787–2793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tian XF, Zhang XW, Chen RX, Wang JW and
Zhang D: Clinical significance of expression of VEGF and bFGF in
thyroid carcinoma. Zhonghua Wai Ke Za Zhi. 42:864–866. 2004.(In
Chinese). PubMed/NCBI
|
|
33
|
Huang YJ, Qi WX, He AN, Sun YJ, Shen Z and
Yao Y: Prognostic value of tissue vascular endothelial growth
factor expression in bladder cancer: A meta-analysis. Asian Pac J
Cancer Prev. 14:645–649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wen L, Wang R, Lu X and You C: Expression
and clinical significance of vascular endothelial growth factor and
fms-related tyrosine kinase 1 in colorectal cancer. Oncol Lett.
9:2414–2418. 2015. View Article : Google Scholar : PubMed/NCBI
|
